

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Although the global COVID-19 pandemic is a public health emergency and presents us with the need to find out as much as we can about the disease as rapidly as possible, we believe that hastily publishing such findings without adequate peer review should be challenged. Especially in times of description of a new disease, much care should be taken to obtain expert review of the findings and any conclusions need to be substantiated by appropriate evaluations and inclusion of controls. Although this literature draw attention to the important question of CNS involvement of COVID-19, the data presented by von Weyhern and colleagues are likely to cause confusion and possibly misdirect future clinical efforts.

We declare no competing interests.

Kristof Egervari, Christian Thomas, Johannes A Lobrinus, Tanja Kuhlmann, Wolfgang Brück, Seth Love, John F Crary, Christine Stadelmann, Werner Paulus, *Doron Merkler doron.merkler@unige.ch

Department of Pathology and Immunology, Division of Clinical Pathology, Geneva University Hospitals, Geneva 1211, Switzerland (KE, JAL, DM); Institute of Neuropathology, University Hospital Münster, Münster, Germany (CT, TK, WP); Institute of Neuropathology, University Medical Center, Göttingen, Germany (WB, CS); University of Bristol Medical School, Southmead Hospital, Bristol, UK (SL); Neuropathology Brain Bank & Research CoRE, Department of Pathology, Nash Family Department of Neuroscience, Ronald M Loeb Center for Alzheimer's Disease, and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai. New York, NY, USA (IFC)

- von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet 2020; 395: e109.
- Jortner BS. The return of the dark neuron.
 A histological artifact complicating contemporary neurotoxicologic evaluation.
 Neurotoxicology 2006; 27: 628–34.
- 3 Solomon IH, Normandin E, Bhattacharyya S, et al Neuropathological features of Covid-19. N Eng J Med 2020; 383: 989–92.

Claus Hann von Weyhern and colleagues¹ describe autopsy findings of six patients who died of COVID-19. Better understanding of the central effects of COVID-19 is crucial, and we read with great interest their findings

that included pan-encephalitis and meningitis in all six patients, regardless of whether cause of death was due to cardiorespiratory failure, pulmonary embolism, or intracranial haemorrhage. However, the images provided in the appendix of the Correspondence¹ do not clearly show meningitis or encephalitis. Shrunken neurons are a common histological finding in autopsy brains and are often observed in neurologically normal cases without any specific pathological change, and the small cells indicated as infiltrating lymphocytes are difficult to distinguish from glial cells in the absence of an immunostain showing interstitial lymphocytes. For example, we show similar findings in a section of a normal neocortex (appendix). Although neuron loss was observed by von Weyhern and colleagues, neuronophagia and microglial nodules were not described. Additionally, perivascular lymphocytes are not diagnostic of viral meningitis or encephalitis but perhaps suggest that COVID-19 is associated with vascular alterations.

The findings of published cases and our own limited experience with COVID-19 disease pathology support that when brain pathology is present, it is apparently often associated with vascular changes, such as thrombi or thromboemboli, rather than primary involvement of the CNS. Although instances with neuropathology consistent with severe acute respiratory syndrome coronavirus 2 encephalitis have been reported, these changes are generally mild and variable.²⁻⁴

We declare no competing interests.

*MacLean P Nasrallah, Zissimos Mourelatos, Edward B Lee maclean.nasrallah@pennmedicine. upenn.edu


Division of Neuropathology, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA

 von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet 2020; 395: e109.

- 2 Bryce C, Grimes Z, Pujadas E, et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. medRxiv 2020; published online May 22. https://doi.org/10.1101/ 2020.05.18.20099960 (preprint).
- Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol 2020; 140: 1–6.
- 4 Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of Covid-19. N Engl J Med 2020; 383: 989–92.

Authors' reply

We welcome the opportunity to respond to the comments about our Correspondence.¹ To increase the availability of data, we reported our findings, which were produced by a team that included an experienced neuropathologist and was subjected to the *The Lancet's* peer-review process. The three responses are similar as they all challenge our interpretation of the findings presented. Striking is the fact that the three responses disagree among themselves, with each offering yet another interpretation.



In the absence of specific morphological alterations, shrinking is often the only indication of necrosis or apoptosis. Aware of the hypoxic origin of similar morphological alterations, we used the general level of hypoxic injury to vulnerable CA1 areas of the hippocampus and Purkinje cells in the cerebellum as a baseline. Because we did not observe hypoxic injury in these areas, we do not attribute the observed morphological alterations to hypoxia.

We concede that the term panencephalitis was poorly chosen. In the neuropathological literature, pan-encephalitis refers to a fulminant



See Online for appendix

